Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies (Q37983692)

26 August 2017

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies (English)

1 reference

magnetic resonance imaging

26 August 2017

0 references

author

Gordon C. Jayson

5

1 reference

26 August 2017

James P B O'Connor

1

1 reference

26 August 2017

Alan Jackson

2

1 reference

26 August 2017

Geoff J M Parker

3

1 reference

26 August 2017

Caleb Roberts

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

14 February 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

167-177

1 reference

26 August 2017

3

1 reference

Functional imaging in phase I studies: decorations or decision making?

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Antiangiogenic Therapy: More Promise and, Yet Again, More Questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

The effect of blood inflow and B(1)-field inhomogeneity on measurement of the arterial input function in axial 3D spoiled gradient echo dynamic contrast-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhancedT1-weighted MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Limitations of dynamic contrast-enhanced MRI in monitoring radiation-induced changes in the fraction of radiobiologically hypoxic cells in human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Translating cancer research into targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Multiparametric imaging of tumor response to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Measuring response in a post-RECIST world: from black and white to shades of grey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

What is targeted therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.2

A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22330689

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22330689

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22330689

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2012.2

1 reference

26 August 2017

1 reference